



●► **Specialised Therapeutics**

(TGA, Approval)

Specialised Therapeutics' YORVIPATH has been approved in Australia for the treatment of chronic hypoparathyroidism

●► **Boehringer Ingelheim**

(FDA, Priority review)

Boehringer's zongertinib has been granted priority review by the FDA for HER2-mutant advanced non-small cell lung cancer

●► **PTC Therapeutics**

(FDA, Priority review)

The FDA has accepted for filing PTC Therapeutics' NDA for vatiquinone for the treatment of children and adults living with Friedreich's ataxia and granted priority review

●► **Innovent**

(NMPA, Priority review)

Innovent's NDA for ipilimumab injection has been accepted by the NMPA and granted Priority Review Designation in combination with sintilimab as neoadjuvant treatment for colon cancer





●► **Clarity Pharmaceuticals**

(FDA, FTD)

Clarity secures FDA Fast Track Designation for Cu-67 SAR-bisPSMA in metastatic castration-resistant prostate cancer

●► **Diablo Clinical Research + Flourish Research** *(Acquisition)*

Flourish Research Acquires Diablo Clinical Research

●► **Pillar Biosciences**

(Agreement)

Pillar Biosciences has entered into a strategic NGS automation application development agreement and co-marketing partnership with Hamilton Company

●► **KYORIN + Cyrano Therapeutics**

(Agreement)

KYORIN+Cyrano Therapeutics sign an option agreement for CYR-064 to address post-viral smell loss in Japan

